Seq Biomarque LLC

Seq Biomarque LLC, based in Anaheim, CA, is a leading research company focused on developing molecular blood-based biomarker tests for Alzheimer's Disease (AD). With guidance from global leaders in AD clinical research, their scientific team is working on a non-invasive, highly sensitive, and cost-effective diagnostic test that evaluates biomarkers throughout the three phases of the disease. Seq Biomarque is particularly interested in novel biomarkers associated with early detection and the preclinical stages of AD, as well as mid- to late-stage biomarkers for monitoring therapeutic efficacy.

As part of their research, Seq Biomarque is developing biomarker tests for traditional markers of AD pathology, such as Tau and Beta-Amyloid, while also focusing on novel blood-based biomarkers directly relevant to the diagnostic AD continuum. Their goal is to create a multifactor AD biomarker panel that complements existing clinical assessments and neuro-imaging tests, providing additional information for optimal therapeutic AD patient care. With an expandable test platform, Seq Biomarque aims to include new biomarkers and conduct high-throughput simultaneous testing of multiple independent specimens.

Generated from the website